RDNA-10. HISTOPATHOLOGICAL AND GENOMIC CHARACTERIZATION OF GLIOBLASTOMA (GBM) RESECTED AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY

BACKGROUND: TTFields are FDA-approved for treatment of newly-diagnosed and recurrent glioblastoma. In this study, GBMs from one patient pre- and post-TTFields monotherapy were analyzed by immunohistochemistry (IHC) and array comparative genomic hybridization (aCGH) to examine potential TTFields-indu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Michelhaugh, Sharon, Kiousis, Sam, Mittal, Sandeep
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217519/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.925
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares